^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NLM-001

    i
    Other names: NLM-001
    Associations

    News

    Trials
    Company:
    Nelum
    Drug class:
    Hedgehog protein inhibitor
    Associations

    News

    Trials
    1year
    NUMANTIA: Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, Nelum Corp | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • zalifrelimab (UGN-301) • NLM-001
    1year
    NUMANTIA: Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, Nelum Corp | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • zalifrelimab (UGN-301) • NLM-001
    2years
    NUMANTIA: Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, Nelum Corp | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • zalifrelimab (UGN-301) • NLM-001
    over2years
    NUMANTIA: Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Nelum Corp | Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Jun 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • zalifrelimab (UGN-301) • NLM-001